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evaluate their impact on gefitinib efficacy. BMI was catego-
rized as underweight (<18.5 kg/m2), normal (18.5–25 kg/
m2), and overweight (≥25 kg/m2).
Results The median BSA and BW were 1.48  m2 and 
53 kg, respectively. The overall response rate, progression-
free survival (PFS), and overall survival (OS) were 65.2%, 
12.2, and 24.2 months, respectively. There were no sig-
nificant differences in clinical outcomes according to BSA, 
BW, or BMI alone. Subgroup analysis based on the muta-
tion type and BSA revealed no significant differences in 
PFS between the groups; however, the median OS in those 
with exon 19 deletion combined with low BSA was signifi-
cantly favorable compared with the other groups.
Conclusions Gefitinib efficacy in patients with NSCLC 
harboring sensitive EGFR mutations did not differ accord-
ing to BSA, BW, and BMI. However, OS was superior in 
patients with both the exon 19 deletion and low BSA.
Abstract 
Purpose In patients with epidermal growth factor recep-
tor (EGFR)-mutated, advanced, non-small cell lung can-
cer (NSCLC), common gefitinib-sensitive EGFR muta-
tions that predict a greater response to therapy include the 
exon 19 deletion and L858R point mutation. The objective 
of this study was to evaluate whether body surface area 
(BSA), body weight (BW), and body mass index (BMI) 
affect gefitinib efficacy in such patients.
Methods The medical charts of 138 consecutive patients 
with advanced NSCLC harboring sensitive EGFR muta-
tions, who underwent gefitinib treatment, were reviewed. 
The median BSA and BW were used as cutoff values to 
H. Imai and T. Kuwako contributed equally to this work.
Electronic supplementary material The online version of this 
article (doi:10.1007/s00280-016-3232-2) contains supplementary 
material, which is available to authorized users.
 * Hisao Imai 
 m06701014@gunma-u.ac.jp
 * Kyoichi Kaira 
 kkaira1970@yahoo.co.jp
1 Department of Medicine and Molecular Science, Gunma 
University Graduate School of Medicine, Maebashi, Gunma, 
Japan
2 Department of Respiratory Medicine, Gunma Prefectural 
Cancer Center, 617-1, Takahayashi-nishi, Ohta, 
Gunma 373-8550, Japan
3 Division of Respiratory Medicine, National Hospital 
Organization Shibukawa Medical Center, Shibukawa, 
Gunma, Japan
4 Department of Oncology Clinical Development, Gunma 
University Graduate School of Medicine, 3-39-15, 
Showa-machi, Maebashi, Gunma 371-8511, Japan
5 Division of Internal Medicine, Kiryu Kosei General Hospital, 
Kiryu, Gunma, Japan
6 Division of General Thoracic Surgery, Integrative Center 
of General Surgery, Gunma University Hospital, 3-39-15, 
Showa-machi, Maebashi, Gunma 371-8511, Japan
7 Division of Internal Medicine, Isesaki Municipal Hospital, 
Isesaki, Gunma, Japan
8 Division of Internal Medicine, Public Tomioka General 
Hospital, Tomioka, Gunma, Japan
9 Division of Respiratory Medicine, Maebashi Red Cross 
Hospital, Maebashi, Gunma, Japan
498 Cancer Chemother Pharmacol (2017) 79:497–505
1 3
Keywords Advanced non-small cell lung cancer · EGFR 
mutations · Gefitinib · Body surface area · Body weight · 
Body mass index
Introduction
Lung cancer is the most common cause of cancer-related 
mortality worldwide, with non-small cell lung can-
cer (NSCLC) accounting for ~85% of all cases [1]. Most 
patients with NSCLC are diagnosed at the advanced stages 
(Stages IIIB and IV), which are associated with particularly 
poor prognoses.
Gefitinib, an epidermal growth factor receptor tyrosine 
kinase inhibitor (EGFR-TKI), is a first-line treatment for 
patients with NSCLC harboring sensitive EGFR mutations 
[2–4]. Although many patients initially achieve clinical 
remission or disease control with first-line chemotherapy, 
most subsequently experience disease progression and 
death. The high response rate (RR) for gefitinib is asso-
ciated with the presence of tumor cells harboring active 
EGFR mutations such as in-frame deletions in exon 19 
or point mutations in exon 21 (e.g., L858R) [5–7]. Sev-
eral phase III trials, which compared platinum-containing 
chemotherapy to gefitinib in the first-line setting, demon-
strated that gefitinib significantly improved progression-
free survival (PFS) in patients with EGFR-activating muta-
tions [2–4]. Meta-analyses have clearly indicated improved 
PFS and superior RRs in patients with EGFR mutations 
who underwent EGFR-TKI therapy compared with those 
who underwent chemotherapy using cytotoxic drugs 
[8–10]. Therefore, EGFR-TKIs are considered a stand-
ard regimen for patients with advanced NSCLC harboring 
EGFR mutations.
The IDEAL 1 and IDEAL 2 studies determined the 
standard dose of gefitinib to be 250 mg/day, which has been 
prescribed irrespective of body size [11, 12]. However, this 
dose was determined before EGFR mutations were identi-
fied as predictors of PFS and RR to EGFR–TKIs. A previ-
ous study demonstrated that body surface area (BSA) influ-
enced gefitinib efficacy in patients with advanced NSCLC 
who harbored EGFR mutations [13, 14], although contrary 
reports finding no effect of BSA also exist [15]. While 
BSA-based and body weight (BW)-based dose adjustments 
are made for chemotherapy with cytotoxic agents and bev-
acizumab-based chemotherapy, respectively, it is unknown 
whether BSA- or BW-based dose adjustments could affect 
gefitinib efficacy in patients with NSCLC harboring EGFR 
mutations. Furthermore, a previous clinical trial reported 
that higher body mass index (BMI) among patients with 
advanced NSCLC significantly affected survival [16]. The 
objective of the present study was to determine whether 
BSA, BW or BMI could affect the efficacy of first-line 
gefitinib in Japanese patients with advanced NSCLC har-
boring gefitinib-sensitive EGFR mutations. We also evalu-
ated PFS and overall survival (OS) according to EGFR 
mutation type (exon 19 deletion and exon 21 L858R) 
because they constitute ~90% of all EGFR mutation-pos-
itive lung adenocarcinomas, and are strongly associated 
with robust responses to EGFR-TKIs [17, 18]. Moreover, 
patients with EGFR exon 19 deletion tumors have shown 
improved outcomes with EGFR-TKIs compared to patients 
with exon 21 L858R-positive tumors [19, 20].
Materials and methods
In this retrospective study, we evaluated 138 consecutive 
patients with advanced NSCLC harboring sensitive EGFR 
mutations who were treated with first-line gefitinib, between 
January 2006 and December 2012, across 7 Japanese institu-
tions (Gunma Prefectural Cancer Center, Gunma University 
Hospital, National Hospital Organization Shibukawa Medi-
cal Center, Kiryu Kosei General Hospital, Isesaki Municipal 
Hospital, Public Tomioka General Hospital, and Maebashi 
Red Cross Hospital). The histological diagnosis and staging 
of NSCLC were based on the World Health Organization 
classification and the tumor–node–metastasis staging system 
[21], respectively. The eligibility criteria included patients 
with histologically or cytologically confirmed advanced 
NSCLC (unresectable stage III/IV disease or recurrence 
according to the new Union for International Cancer Control 
criteria, version 7) whose tumors harbored drug-sensitive 
EGFR mutations (exon 19 deletion/exon 21 L858R), and 
who were undergoing continuous first-line gefitinib treat-
ment. Patients who did not have at least one measurable 
lesion according to the Response Evaluation Criteria in Solid 
Tumors (RECIST) 1.1 criteria [22] were excluded. Before 
therapy, each patient underwent a physical examination, chest 
radiography, thorax and abdomen computed tomography, 
bone scintigraphy or 18F-fluorodeoxyglucose positron emis-
sion tomography, and brain computed tomography or mag-
netic resonance imaging to determine the TNM stage. Patient 
characteristics including sex, age at diagnosis, Eastern Coop-
erative Oncology Group (ECOG) performance status (PS) at 
the start of gefitinib treatment, clinical stage, tumor histol-
ogy, smoking status, EGFR mutation type, BW, height, and 
number of regimens following first-line gefitinib were deter-
mined by a retrospective chart review. Patients were classi-
fied according to smoking status as current smokers, former 
light smokers (having smoked for a total of ≤10 pack-years 
plus smoking cessation at least 15 years previously), and 
never-smokers (a lifetime history of having smoked <100 
cigarettes). We used the following formula to calculate BSA: 
BSA  (m2) = [body weight (kg)]0.425 × [height (cm)]0.725 × 
0.007184 [23]. A clinical chart search was performed for 
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each selected patients at each hospital. The Institutional 
Review Boards of each institution approved the study proto-
col, although the requirement for written informed consent 
was waived.
Genomic DNA was extracted from the tumor samples, 
and EGFR mutations in exons 18–21 were analyzed as pre-
viously described [24, 25]. All patients were EGFR-TKI 
naïve, and underwent first-line oral gefitinib (250 mg/day). 
Treatment continued until disease progression, the appear-
ance of intolerable toxicity, or withdrawal of consent.
The best overall response and maximum tumor shrink-
age were recorded as the tumor responses. Radiographic 
tumor responses were defined according to the RECIST 
v1.1 [22] as complete response (CR), the disappearance of 
all target lesions; partial response (PR), a decrease in the 
sum of the target lesion diameters of at least 30% compared 
with baseline; progressive disease (PD), an increase of at 
least 20% in the sum of the target lesion diameters com-
pared with the smallest sum during the study; stable disease 
(SD), insufficient shrinkage or expansion to qualify as PR 
or PD. The differences in the RRs according to the patients’ 
characteristics were compared using Fisher’s exact test. 
The distributions of categorical characteristics according to 
whether the patients’ BSA was ≥1.48 m2 (high-BSA group) 
or <1.48 m2 (low-BSA group) were compared using Fish-
er’s exact test. The distributions of categorical characteris-
tics according to whether patients’ BW was ≥53 kg (high-
BW group) or <53  kg (low-BW group) were compared 
using Fisher’s exact test. BMI at the start of treatment was 
defined as weight (kg) divided by the height (m) squared. 
Patients were stratified into BMI groups as defined by the 
World Health Organization: underweight (BMI < 18.5  kg/
m2), normal weight (BMI 18.5–25 kg/m2), and overweight 
(BMI ≥ 25  kg/m2). PFS was calculated from the start of 
treatment until PD or death from any cause, and OS was 
recorded from the first day of treatment until death or was 
censored at the date of the last follow-up. Survival curves 
were plotted using the Kaplan–Meier method and the dif-
ferences in survival times were analyzed using the log-rank 
test. A p value <0.05 was considered statistically signifi-
cant. After the failure of first-line gefitinib therapy, patients 
were permitted any subsequent treatment(s), including the 
continuation of gefitinib treatment. All statistical analyses 
were performed using JMP, version 11.0, for Windows 
(SAS Institute, Cary, NC).
Results
Patient characteristics
The clinical characteristics of all 138 patients are listed 
in Table  1. The majority of patients had a good PS 
(0–1), adenocarcinoma, and stage IV disease or post-
operative recurrence. There were some uneven distri-
butions in patient characteristics between the groups 
evaluated (Table  2). Compared with those in the low-
BSA group, in the high-BSA group a greater percent-
age were male (p < 0.0001), were younger than 75 years 
old (p < 0.0007), and were current or former smokers 
(p < 0.0005). Similarly, compared with those in the low-
BW group, in the high-BW group a greater percentage of 
patients were male (p < 0.0002), were younger than 75 
Table 1  Patient characteristics
Performance status was determined using the Eastern Cooperative 
Oncology Group criteria
EGFR epidermal growth factor receptor, BSA body surface area, BW 
















 IV or postoperative recurrence 128 (92.8)
Histology
 Adenocarcinoma 135 (97.8)
 Other/not specified 3 (2.2)
Smoking history
 Current or former 36 (26.0)
 Never 102 (74.0)
EGFR mutation
 Exon 19 deletion 66 (47.9)
 Exon 21 L858R 72 (52.1)
BSA  (m2), median (range) 1.48 (1.09–1.98)
 <1.48 69 (50.0)
 ≥1.48 69 (50.0)
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years old (p < 0.017), and were current or former smok-
ers (p < 0.003). There were no significant differences in 
patient characteristics for any of the BMI groups.
Response to gefitinib according to BSA, BW, and BMI
An objective response was obtained in 90 of 138 patients, 
including a CR in 11 patients, and the overall RR was 
65.2%. The objective tumor responses according to patient 
characteristics are shown in Supplementary Table  1. The 
RRs were 63.8 and 66.7% in the high- and low-BSA groups, 
respectively (p = 0.72). The RRs were 63.4 and 67.2% in 
the high- and low-BW groups, respectively (p = 0.64). Fur-
thermore, the RR was 73.9% in the underweight group, 
62.2% in the normal weight group, and 66.7% in the over-
weight group (p = 0.56). There were no significant differ-
ences in sex, age, PS, clinical stage, smoking history, or 
type of EGFR mutation between the groups.
PFS after gefitinib therapy according to BSA, BW, 
and BMI alone
The median PFS time for the whole study population was 
12.0 (95% CI 9.8–14.0) months. The median PFS times 
in the low- and high-BSA groups were 11.5 (95% CI 
7.7–15.1) and 12.2 (95% CI 9.2–14.1) months, respectively 
(p = 0.78, log-rank, Fig. 1a). We also evaluated 1.30, 1.40, 
1.50, and 1.60  m2 as BSA cutoff values in the log-rank 
analysis, but none of the differences in PFS were significant 
(BSA 1.30 m2: low vs. high 12.9 vs. 11.3 months, p = 0.52; 
BSA 1.40 m2: low vs. high 11.5 vs. 12.2 months, p = 0.99; 
BSA 1.50 m2: low vs. high 11.5 vs. 12.2 months, p = 0.90; 
BSA 1.60 m2: low vs. high 12.0 vs. 12.2 months, p = 0.96).
The median PFS times in the low- and high-BW groups 
were 10.8 (95% CI 6.9–14.5) and 12.2 (95% CI 9.8–15.6) 
months, respectively (p = 0.46, log-rank, Fig. 1b). We also 
evaluated 40, and 60 kg as BW cutoff values in the log-rank 
analysis, but none of the differences in PFS were significant 
(BW 40 kg: low vs. high 9.1 vs. 12.2 months, p = 0.79; BW 
60 kg: low vs. high 12.0 vs. 12.2 months, p = 0.79).
The median PFS times were 10.6 (95% CI 6.1–12.9), 
12.0 (95% CI 9.0–15.1), 13.1 (95% CI 7.0–18.2) months in 
the underweight, normal weight, and overweight groups, 
respectively (p = 0.52, log-rank, Fig. 1c).
OS after gefitinib therapy according to BSA, BW, 
and BMI alone
The median OS time for the whole patient population was 
24.2 (95% CI 20.7–33.1) months. The median OS times 
in the low- and high-BSA groups were 26.8 (95% CI 
Table 2  Characteristics according to BSA, BW, and BMI
Performance status was determined using the Eastern Cooperative Oncology Group criteria
BSA body surface area, BW body weight, BMI body mass index, PS performance status, EGFR epidermal growth factor receptor
*Fisher’s exact test. Italic p values are statistically significant (p < 0.05)
Characteristic BSA  (m2), n (%) p* BW (kg), n (%) p* BMI (kg/m2), n (%) p*
≥1.48 <1.48 ≥53 <53 <18.5 18.5–25 ≥25
Sex
 Male 29 (80.6) 7 (19.4) <0.0001 28 (77.8) 8 (22.2) 0.0002 3 (8.3) 24 (66.7) 9 (25.0) 0.28
 Female 40 (39.2) 62 (60.8) 43 (42.2) 59 (57.8) 20 (19.6) 58 (56.9) 24 (23.5)
Age (years)
 <75 46 (63.9) 26 (36.1) 0.0007 44 (61.1) 28 (38.9) 0.017 11 (15.3) 43 (59.7) 18 (25.0) 0.88
 ≥75 23 (34.8) 43 (65.2) 27 (40.9) 39 (59.1) 12 (18.2) 39 (59.1) 15 (22.7)
PS
 0–1 56 (51.8) 52 (48.2) 0.40 58 (53.7) 50 (46.3) 0.31 14 (12.9) 68 (63.0) 26 (24.1) 0.07
 2–4 13 (43.3) 17 (56.7) 13 (51.5) 17 (48.5) 9 (30.0) 14 (46.7) 7 (23.3)
Clinical stage
 IIIB 4 (40.0) 6 (60.0) 0.51 5 (50.0) 5 (50.0) 0.92 2 (20.0) 6 (60.0) 2 (20.0) 0.93
 IV or rec 65 (50.8) 63 (49.2) 66 (51.6) 62 (48.4) 21 (16.4) 76 (59.4) 31 (24.2)
Smoking history
 Current or former 27 (75.0) 9 (25.0) 0.0005 26 (72.2) 10 (27.8) 0.003 4 (11.1) 23 (63.9) 9 (25.0) 0.57
 Never 42 (41.2) 60 (58.8) 45 (44.1) 57 (55.9) 19 (18.6) 59 (57.9) 24 (23.5)
EGFR mutation
 Exon 19 deletion 34 (51.5) 32 (48.5) 0.73 38 (57.6) 28 (42.4) 0.16 8 (12.1) 44 (66.7) 14 (21.2) 0.21
 Exon 21 L858R 35 (48.6) 37 (51.4) 33 (45.8) 39 (54.2) 15 (20.8) 38 (52.8) 19 (26.4)
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20.1–35.3) and 24.2 (95% CI 19.6–33.1) months, respec-
tively (p = 0.90, log-rank, Fig. 1d).
The median OS times in the low- and high-BW groups 
were 21.9 (95% CI 19.2–33.2) and 28.9 (95% CI 21.4–38.8) 
months, respectively (p = 0.22, log-rank, Fig. 1e).
The median OS times were 19.2 (95% CI 13.9–26.8), 
23.3 (95% CI 20.6–34.5), and 33.1 (95% CI 17.3–38.8) 
months in the underweight, normal weight, and overweight 
groups, respectively (p = 0.30, log-rank, Fig. 1f).
PFS and OS to gefitinib therapy according to EGFR 
mutation type and BSA
PFS and OS were analyzed according to EGFR mutation 
type and BSA. The median PFS times were 10.6 (95% 
CI 6.9–18.6) and 13.7 (95% CI 5.7–15.8) months in the 
exon 19 deletion_low-BSA and exon 21 L858R_low-BSA 
groups, respectively (p = 0.49, log-rank, Fig.  2a). The 
median PFS times were 11.2 (95% CI 8.0–15.1) and 12.2 
(95% CI 7.4–16.3) months in the exon 19 deletion_high-
BSA and exon 21 L858R_high-BSA groups, respectively 
(p = 0.85, log-rank, Fig. 2b).
The median OS times were 37.9 (95% CI 28.0–55.1) 
and 19.5 (95% CI 13.9–21.9) months in the exon 19 dele-
tion_low-BSA and exon 21 L858R_low-BSA groups, 
respectively (p < 0.05, log-rank, Fig.  2c). The median OS 
times were 23.3 (95% CI 17.3–40.9) and 25.0 (95% CI 
16.2–38.3) months in the exon 19 deletion_high-BSA and 
exon 21 L858R_high-BSA groups, respectively (p = 0.98, 
log-rank, Fig. 2d).
Therefore, because the median OS times in the exon 19 
deletion_low-BSA group were significantly favorable, the 
predictive value of various clinical factors on PFS and OS 
for patients with low-BSA was assessed (Table  3). In the 
univariate analysis, age and PS were significantly asso-
ciated with superior PFS. In the multivariate analysis, 
adjusted for various clinical factors, age (p = 0.01) and PS 
(p = 0.01) were independently associated with superior 
Fig. 1  Kaplan–Meier plots 
showing progression-free and 
overall survival according to 
the measured parameters. a 
The median PFS times in the 
low- and high-BSA groups. b 
The median PFS times in the 
low- and high-BW groups. c 
The median PFS times in the 
underweight, normal weight, 
and overweight groups. d The 
median OS times in the low- 
and high-BSA groups. e The 
median OS times in the low- 
and high-BW groups. f The 
median OS times in the under-
weight, normal weight, and 
overweight groups, respectively
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PFS. Elderly age (≥75 years) was associated with a longer 
median PFS compared with younger age (<75 years) 
(14.6 vs. 8.7 months, log-rank p = 0.02). Similarly, a bet-
ter PS score (0–1) was associated with a longer median 
PFS compared with poorer PS scores (2–4) (14.5 vs. 5.6 
months, log-rank p < 0.01). In the univariate analysis, PS 
and EGFR mutation type were significantly associated 
with superior OS. In the multivariate analysis, adjusted for 
various clinical factors, PS (p < 0.01) and EGFR mutation 
type (p < 0.01) were independently associated with superior 
OS. Better PS scores (0–1) were associated with a longer 
median OS compared with worse PS scores (2–4) (33.2 vs. 
10.1 months, log-rank p < 0.01). Similarly, patients with 
an exon 19 deletion had a longer median OS compared 
to those with an exon 21 L858R mutation (37.9 vs. 19.5 
months, log-rank, p < 0.01).
Discussion
The present study showed that BSA, BW, and BMI alone 
did not affect the clinical outcomes of gefitinib therapy 
including RR, PFS, and OS in patients with advanced 
NSCLC harboring an EGFR mutation. Furthermore, BSA 
in combination with EGFR mutation type did not affect OS. 
However, in patients with a low BSA (<1.48  m2), EGFR 
mutation type significantly affected OS following gefitinib 
therapy. Specifically, in patients with a low BSA, compared 
with the L858R mutation, the exon 19 deletion conferred 
superior OS times following gefitinib therapy.
For the 138 patients in the present study, and those 
enrolled in 2 Japanese randomized phase III studies 
(NEJ002 and WJTOG3405) [3, 4], there were no major dif-
ferences in the distribution of patient characteristics. There-
fore, the population in the present study was considered 
suitable for an evaluation of gefitinib efficacy in patients 
with advanced NSCLC harboring an EGFR mutation.
Ichihara et  al. reported a retrospective study showing 
that BSA affected PFS in patients with NSCLC harboring 
an EGFR mutation who underwent gefitinib therapy [13]. 
They stated that a post hoc sub-analysis of the data reported 
by Ando et al. supported their findings, i.e., that BSA val-
ues ≥1.5  m2 were associated with an inferior response 
to gefitinib [26]. However, Ando et  al. performed their 
analysis irrespective of EGFR mutation status. A previ-
ous study found that EGFR mutations were more frequent 
among non-smokers than smokers, and more frequent 
among females than males [27]. Therefore, it is reason-
able to assume that in Ando et  al., there were more male 
patients with wild-type EGFR compared to females with 
an EGFR mutation in the high-BSA group, and, accord-
ingly, the high-BSA group had poor responses to gefitinib 
in their study [26]. In fact, Ando et al. found that BSA was 
not independently predictive of antitumor response survival 
[26].
In the present study, subgroup analyses examining dif-
ferent EGFR mutations in the low-BSA group showed a 
significant improvement in OS in patients with tumors 
harboring the exon 19 deletion mutation compared with 
that in patients with tumors harboring the exon 21 L858R 
mutation. By contrast, there were no significant differences 
Fig. 2  Kaplan–Meier plots 
showing progression-free and 
overall survival according to 
both BSA and mutation type. 
a The median PFS times in 
the exon 19 deletion_low-BSA 
and exon 21 L858R_low-BSA 
groups. b The median PFS 
times in the exon 19 dele-
tion_high-BSA and exon 21 
L858R_high-BSA groups. c 
The median OS times in the 
exon 19 deletion_low-BSA 
and exon 21 L858R_low-BSA 
groups; the difference was 
statistically significant. d The 
median OS times in the exon 19 
deletion_high-BSA and exon 21 
L858R_high-BSA groups
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in OS in the high-BSA group according to the type of 
mutation present. As previously mentioned, these 2 muta-
tions constitute the majority of EGFR mutation-positive 
lung adenocarcinomas [17] and can affect responses and 
outcomes to EGFR-TKIs [18–20, 28]. However, the rea-
sons for such differences in response to EGFR-TKIs are 
unknown. One possibility is that exon 19 deletion harbor-
ing tumors are more efficiently inhibited by gefitinib com-
pared with exon 21 L858R mutation harboring tumors, 
although in  vitro studies do not support this hypothesis. 
NSCLC cell lines bearing exon 19 deletion or L858R muta-
tions showed similar growth inhibition profiles in response 
to gefitinib or erlotinib [29, 30]. Furthermore, EGFR phos-
phorylation is completely inhibited by equivalent concen-
trations of gefitinib in NIH-3T3 cells expressing either an 
exon 21 L858R mutation or an exon 19 deletion [30]. An 
alternative hypothesis is that the exon 20 T790M muta-
tion, which has been associated with acquired resistance to 
EGFR-TKIs [31, 32], might occur more frequently in the 
presence of an exon 21 L858R mutation compared with in 
the presence of an exon 19 deletion. However, the presently 
available data are too limited to draw any such conclusions, 
and continued analyses of tumor specimens from patients 
who develop acquired resistance to gefitinib or erlotinib are 
needed to answer this question.
Although mutation type affected the median OS in the 
low-BSA group, it did not affect the median PFS. This 
is most likely because of bias in the number of patients 
between the two groups. However, one possibility is 
that patients with exon 19 deletion-positive tumors have 
improved outcomes following EGFR-TKIs therapy com-
pared to those with exon 21 L858R mutations, as men-
tioned above. To date, dose adjustment according to BSA 
has not been approved for any molecular-targeted agent. 
Although erlotinib and afatinib require such analysis, our 
findings suggest that the potential influence of BSA on 
the pharmacokinetic and pharmacodynamic variability of 
EGFR-TKIs could be considered the next step in investigat-
ing the clinical meaningfulness of BSA-based dosing dur-
ing EGFR-TKI treatment.
This study has several limitations. First, it was a retro-
spective analysis, and the results could not be regarded as 
completely definitive. Second, reducing, skipping, or delay-
ing the planned chemotherapy was performed at the attend-
ing physician’s discretion. To minimize potential bias, all 
consecutive patients who were treated at our institutions 
were included in the analysis, and the patients’ original 
charts were thoroughly reviewed. Third, the study sample 
size was small, although we believe that the results of the 
present study are useful because it includes a greater num-
ber of patients compared with any previous reports. Fourth, 
we did not include pharmacokinetic data in the analysis; 




























































































































































































































































































































































































































































504 Cancer Chemother Pharmacol (2017) 79:497–505
1 3
inter-patient pharmacokinetic variability, resulting in the 
observed differences in OS. A pharmacokinetics–pharma-
codynamics study is warranted to clarify this issue. Finally, 
since the cutoff value for BSA was different from that com-
monly used in the Western countries (i.e., 1.7 m2) [33], fur-
ther assessments would be needed to extrapolate the find-
ings to Europeans and North Americans. Because of these 
limitations, the data should be interpreted with caution.
In conclusion, the efficacy of gefitinib in patients with 
advanced NSCLC harboring sensitive EGFR mutations 
does not differ according to BSA, BW, or BMI. However, 
the OS of those with an exon 19 deletion combined with 
low BSA was significantly favorable. Our findings suggest 
that adjustment of gefitinib dose based on EGFR mutation 
type could be considered the next step in investigating the 
clinical implications of BSA-based dosing during gefitinib 
monotherapy.
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